[The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
To evaluate the value of serum CA 125 antigen in monitoring of treatment of ovarian carcinoma, serum levels of this marker were monthly assayed during treatment and follow-up period in a group of 112 patients. CA 125 levels decreased in all 67 patients with remission. In a group of 41 patients with progressive disease, in 38 (93%) CA 125 levels increased, and in 3 (7%) - remained elevated. CA 125 became negative in all patients with clinical complete remission, although in 14 (38%) patients in this group second-look laparotomy revealed microscopic disease. In 12 of 15 patients with complete pathologic remission the increase of CA 125 preceded (2 to 58 weeks, median - 12 weeks) the recurrence of the disease. Time to progression depended on the increase rate of the antigen level.
Zaucha
R
R
Kliniki Onkologii i Radioterapii Akademii Medycznej w Gdańsku.
Kobierska
A
A
D000328:Adult; D000368:Aged; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies
D018394:CA-125 Antigen
Wartość oznaczania poziomu CA 125 w surowicy w monitorowaniu leczenia chorych na raka jajnika.